The complexity of preclinical studies for oncology drug development is at an all-time high with the unprecedented growth of novel immunotherapies and the continued evolution of targeted therapies.
TORONTO (PRWEB) April 21, 2020
- Maryland Franklin, PhD, Executive Director of Scientific Development, Preclinical Oncology
- Suso Platero, PhD, Global Lead, Precision Medicine and Head, Biomarker Solutions Center
- Kamal Veer Saini, MD, Senior Medical Director – Oncology
Oncology drug development is in a period of unprecedented innovation, driven by the evolution of targeted therapies and the explosion of immuno-oncology agents. With this growth, however, comes a number of scientific challenges that require a more integrated approach to the overall drug development process.
The complexity of preclinical studies for oncology drug development is at an all-time high with the unprecedented growth of novel immunotherapies and the continued evolution of targeted therapies. This has resulted in sustained use of tried and true models like human tumor xenografts and genetically modified mouse models. It has also meant the emergence of a wider variety of models such as the rebirth of syngeneic mouse models and creation and utilization of humanized mouse strategies. Even with all of this, there is no ‘one size fits all’ approach.
Biomarkers also now encompass all areas of immuno-oncology drug development, from discovery to registration, even as companion diagnostics. Predictive biomarkers are enriching immuno-oncology trials with patients more likely to respond to treatment – resulting in better outcomes and accelerated timelines. Finally, new clinical trial designs and changes in regulatory approvals have made it possible for new drugs to reach the market at unprecedented speed.
This webinar is part of a scientific series Covance is offering focused on trends, challenges and opportunities associated with current and future applications in Oncology. Learn more and register for upcoming webinars on topics such as adoptive cell therapies, biomarker technologies for the detection of cancer driver mutations, novel targeted therapies and more.
For more information or to register for this event, visit Trends in Immuno-Oncology from Preclinical Models through Biomarkers and Clinical Trial Design.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks, visit http://xtalks.com.
For information about hosting a webinar, visit http://xtalks.com/why-host-a-webinar/.